WO2006059247A8 - VACCINES, COMPOSITIONS AND METHODS BASED ON STAPHYLOCOCCUS AUREUS IRON-REGULATED SURFACE DETERMINANTS IsdA, IsdB, and IsdC - Google Patents

VACCINES, COMPOSITIONS AND METHODS BASED ON STAPHYLOCOCCUS AUREUS IRON-REGULATED SURFACE DETERMINANTS IsdA, IsdB, and IsdC

Info

Publication number
WO2006059247A8
WO2006059247A8 PCT/IB2005/004126 IB2005004126W WO2006059247A8 WO 2006059247 A8 WO2006059247 A8 WO 2006059247A8 IB 2005004126 W IB2005004126 W IB 2005004126W WO 2006059247 A8 WO2006059247 A8 WO 2006059247A8
Authority
WO
WIPO (PCT)
Prior art keywords
isdc
isdb
isda
vaccines
staphylococcus aureus
Prior art date
Application number
PCT/IB2005/004126
Other languages
French (fr)
Other versions
WO2006059247A2 (en
WO2006059247A3 (en
Inventor
David E Heinrichs
Christie Vermeiren
Original Assignee
Univ Western Ontario
David E Heinrichs
Christie Vermeiren
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Western Ontario, David E Heinrichs, Christie Vermeiren filed Critical Univ Western Ontario
Priority to CA002581746A priority Critical patent/CA2581746A1/en
Priority to EP05850805A priority patent/EP1812066A4/en
Priority to JP2007537422A priority patent/JP2008517900A/en
Priority to AU2005310981A priority patent/AU2005310981A1/en
Publication of WO2006059247A2 publication Critical patent/WO2006059247A2/en
Publication of WO2006059247A3 publication Critical patent/WO2006059247A3/en
Priority to US11/740,128 priority patent/US20080050361A1/en
Publication of WO2006059247A8 publication Critical patent/WO2006059247A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Abstract

Iron-regulated surface determinant proteins IsdA, IsdB and IsdC from Staphylococcus aureus, as well as antibodies, antisense nucleic acids and siRNA specific to IsdA, IsdB or IsdC are used as vaccines and in method for treating or preventing a disease or condition associated with S. aureus infections Screening assays for identifying agents that inhibit or interfere with the expression level and/or function of IsdA, IsdB or IsdC are also described.
PCT/IB2005/004126 2004-10-25 2005-10-25 VACCINES, COMPOSITIONS AND METHODS BASED ON STAPHYLOCOCCUS AUREUS IRON-REGULATED SURFACE DETERMINANTS IsdA, IsdB, and IsdC WO2006059247A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002581746A CA2581746A1 (en) 2004-10-25 2005-10-25 Staphylococcus aureus isd protein-based anti-infectives
EP05850805A EP1812066A4 (en) 2004-10-25 2005-10-25 VACCINES, COMPOSITIONS AND METHODS BASED ON STAPHYLOCOCCUS AUREUS IRON-REGULATED SURFACE DETERMINANTS IsdA, IsdB, and IsdC
JP2007537422A JP2008517900A (en) 2004-10-25 2005-10-25 Staphylococcus aureus Isd protein-based antiinfectives
AU2005310981A AU2005310981A1 (en) 2004-10-25 2005-10-25 Vaccines, compositions and methods based on Staphylococcus aureus iron-regulated surface determinants IsdA, IsdB, and IsdC
US11/740,128 US20080050361A1 (en) 2004-10-25 2007-04-25 Staphylococcus aureas specific anti-infectives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62192104P 2004-10-25 2004-10-25
US60/621,921 2004-10-25

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/740,128 Continuation-In-Part US20080050361A1 (en) 2004-10-25 2007-04-25 Staphylococcus aureas specific anti-infectives

Publications (3)

Publication Number Publication Date
WO2006059247A2 WO2006059247A2 (en) 2006-06-08
WO2006059247A3 WO2006059247A3 (en) 2006-10-05
WO2006059247A8 true WO2006059247A8 (en) 2007-04-26

Family

ID=36565416

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/004126 WO2006059247A2 (en) 2004-10-25 2005-10-25 VACCINES, COMPOSITIONS AND METHODS BASED ON STAPHYLOCOCCUS AUREUS IRON-REGULATED SURFACE DETERMINANTS IsdA, IsdB, and IsdC

Country Status (6)

Country Link
EP (1) EP1812066A4 (en)
JP (1) JP2008517900A (en)
KR (1) KR20070085457A (en)
AU (1) AU2005310981A1 (en)
CA (1) CA2581746A1 (en)
WO (1) WO2006059247A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
US9315554B2 (en) 2010-07-02 2016-04-19 The University Of Chicago Compositions and methods related to protein A (SpA) variants

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1853306B1 (en) 2005-02-14 2016-06-15 Epitopix, LLC Polypeptides from staphylococcus aureus and methods of use
US20090317421A1 (en) * 2006-01-18 2009-12-24 Dominique Missiakas Compositions and methods related to staphylococcal bacterium proteins
JP2009531387A (en) 2006-03-30 2009-09-03 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Immunogenic composition
WO2008152447A2 (en) * 2006-10-30 2008-12-18 The University Of Western Ontario Staphylococcus aureus specific anti-infectives
US9181329B2 (en) 2007-08-31 2015-11-10 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions
WO2009029831A1 (en) 2007-08-31 2009-03-05 University Of Chicago Methods and compositions related to immunizing against staphylococcal lung diseases and conditions
WO2010014304A1 (en) 2008-07-29 2010-02-04 University Of Chicago Compositions and methods related to staphylococcal bacterium proteins
NZ614557A (en) 2009-03-23 2015-03-27 Epitopix Llc Polypeptides and immunizing compositions containing gram positive polypeptides and methods of use
HUE057713T2 (en) 2009-04-03 2022-05-28 Univ Chicago Compositions and methods related to protein a (spa) variants
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
JP2016515381A (en) * 2013-03-15 2016-05-30 テチュロン インコーポレイテッド Antisense molecules for the treatment of Staphylococcus aureus infections
US9834768B2 (en) 2014-12-31 2017-12-05 Korea Advanced Institute Of Science And Technology Effective method for specific gene silencing using artificial small RNA

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002077183A2 (en) * 2001-03-21 2002-10-03 Elitra Pharmaceuticals, Inc. Identification of essential genes in microorganisms
WO2002102829A2 (en) * 2001-06-15 2002-12-27 Inhibitex, Inc. Cross-reactive monoclonal and polyclonal antibodies which recognize surface proteins from coagulase-negative staphylococci and staphylococcus aureus
CA2453937C (en) * 2001-08-02 2013-05-14 University Of Sheffield Antigenic polypeptides
RU2337108C2 (en) * 2003-07-24 2008-10-27 Мерк Энд Ко., Инк. Polypeptides for induction of protective immune response against staphylococcus aureus
ES2472441T3 (en) * 2004-09-22 2014-07-01 Glaxosmithkline Biologicals S.A. Immunogenic composition for use in staphylococcal vaccination

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9315554B2 (en) 2010-07-02 2016-04-19 The University Of Chicago Compositions and methods related to protein A (SpA) variants
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides

Also Published As

Publication number Publication date
JP2008517900A (en) 2008-05-29
WO2006059247A2 (en) 2006-06-08
CA2581746A1 (en) 2006-06-08
EP1812066A4 (en) 2010-06-30
EP1812066A2 (en) 2007-08-01
WO2006059247A3 (en) 2006-10-05
KR20070085457A (en) 2007-08-27
AU2005310981A1 (en) 2006-06-08

Similar Documents

Publication Publication Date Title
WO2006059247A8 (en) VACCINES, COMPOSITIONS AND METHODS BASED ON STAPHYLOCOCCUS AUREUS IRON-REGULATED SURFACE DETERMINANTS IsdA, IsdB, and IsdC
WO2008152447A3 (en) Staphylococcus aureus specific anti-infectives
WO2006071107A8 (en) Mite composition, use thereof, method for rearing a phytoseiid predatory mite, rearing system for rearing said phytoseiid predatory mite and methods for biological pest control on a crop
ITRM20050068A1 (en) METHOD FOR THE DETECTION OF NUCLEIC ACIDS OF BACTERIAL OR PATENT PATOGEN AGENTS IN URINE.
IN2015KN00290A (en)
PL2314623T3 (en) IL-1beta binding antibodies and fragments thereof
EP2606933A3 (en) Combination of an IAP-inhibitor and a taxane
BRPI0506771A (en) antibody and pharmaceutical composition
NO20064194L (en) Method for modulating IL-23 activity, related reagents
WO2004007743A3 (en) Use of cpg nucleic acids in prion-disease
WO2004069184A3 (en) Methods for treating, preventing and detecting helicobacter infection
WO2020198509A3 (en) Modified oligonucleotides with increased stability
WO2007002587A3 (en) Inhibitors of epstein barr virus nuclear antigen 1
ATE461693T1 (en) METHOD FOR TREATING ACUTE RHINOSINUSITIS
WO2005077046A3 (en) A composition and method of treating mastitis
WO2006113526A3 (en) Prevention of chlamydia infection using a protective antibody
ATE421698T1 (en) PORK INTRINSIC FACTOR
BR0205610B1 (en) process for preparing alkylidene substituted succinic acid esters.
WO2006079121A3 (en) Methods of treating disease with glycosylated interferon
WO2005037231A3 (en) Methods of detecting and treating facioscapulohumeral muscular dystrophy
ATE501129T1 (en) METHOD FOR PRODUCING 2-CHLORINE-5-CHLOROMETHYL-1,3-THIAZOLE
WO2005054548A3 (en) Methods, compositions, and kits for protein crystallization
BRPI0507153A (en) compound, pharmaceutical composition for ophthalmic use, and, process for preparing the ibopamine maleate salt
BR0300234B8 (en) oligomeric composition, method for improving the properties of tanned leather, and, article.
DE60326812D1 (en) Process for the preparation of 4,4-biphenol

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2581746

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007537422

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 11740128

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005310981

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2005310981

Country of ref document: AU

Date of ref document: 20051025

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2005850805

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1020077011878

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2005850805

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 11740128

Country of ref document: US